Gain Contingency, Number of Defendants

No definition available.

Name:	pfe_GainContingencyNumberofDefendants
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly not infringed upon.

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Gain Contingency, Patents Without Court Proceedings, Number

+ References

No definition available.

+ Details

Name:	pfe_GainContingencyPatentsWithoutCourtProceedingsNumber
Namespace Prefix:	pfe_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity has allegedly infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of entity's patents that another entity was found not to have infringed.

+ References

No definition available.

+ Details

Name:	us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusAjantaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_PrecedexPremixMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusFreseniusKabjUSALLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_HospiraVersusParMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_XeljanzMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=pfe_EliquisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)		1 Months Ended								3 Months Ended	12 Months Ended
	Dec. 31, 2019 Patents	Jan. 31, 2020 Patents	Mar. 31, 2019 Patents	Dec. 31, 2018 Patents	Jun. 30, 2018 Patents	Jan. 31, 2018 Patents	Oct. 31, 2017 Patents	Mar. 31, 2017 Patents	Aug. 31, 2015 Patents	Apr. 30, 2017 Defendant Patents	Dec. 31, 2019 Patents	Dec. 31, 2014 Patents
Patent Infringement [Member]
Gain Contingencies [Line Items]
Number of patents without court proceedings							2
Patent Infringement [Member] \| Judicial Ruling [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon					1
Pfizer Versus Ajanta [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon			2
Pfizer Versus Generic Companies [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon			2
Precedex Premix [Member] \| Hospira Versus Amneal Pharmaceuticals LLC [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly not infringed upon												1
Precedex Premix [Member] \| Hospira Versus Amneal Pharmaceuticals LLC [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of patents infringed upon						1
Number of patents not infringed upon expired March 2019			1
Number of patents found not infringed upon						3
Precedex Premix [Member] \| Hospira Versus Fresenius Kabj USA LLC [Member] \| Settled Litigation [Member]
Gain Contingencies [Line Items]
Number of patents found not infringed upon	2			2
Number of patents found not infringed upon subsequently appealed											1
Precedex Premix [Member] \| Hospira Versus Par [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly not infringed upon						4			4
Xeljanz [Member] \| Pfizer Versus Zydus [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon								3
Eliquis [Member] \| Pfizer and BMS Versus Several Generic Manufacturers [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon										3
Number of defendants \| Defendant										25
Number of patents allegedly infringed upon due to expire In December 2019										1
Subsequent Event [Member] \| Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] \| Patent Infringement [Member] \| Pending Litigation [Member]
Gain Contingencies [Line Items]
Number of patents allegedly infringed upon		3